SOPHiA GENETICS SA announced key additions to their leadership team with the hiring of Peter Casasanto as Chief BioPharma Officer and Abhimanyu (Abhi) Verma as Chief Technology Officer. The additions are part of SOPHiA GENETICS' strategy to enhance its business in the pharmaceutical industry. Peter and Abhi will help the company drive deeper with a focus on leveraging data for the BioPharma industry.

Peter brings more than 15 years of life sciences industry experience in business development and sales strategy to SOPHiA GENETICS' growing portfolio. Prior to this role, he was Vice President of New Commercialization Initiatives at CellCarta where he led commercial strategies for corporate initiatives, including companion diagnostics/single-site IVD launch and Go-to-Market strategy for an in-house developed SaaS analytics platform, as well as AI-driven initiatives for multiomic-based insights and predictions. Abhi brings more than 17 years of Life Sciences industry experience in leading global multifunctional organizations to develop technology and data driven capabilities and platforms to accelerate drug R&D and patient access to breakthrough therapies.

Previously, Abhi served at Novartis where he had several leadership roles spanning multiple functions, locations and therapy areas in applied technology innovation, real world evidence, drug development, enterprise technologies, IT strategy, data science and AI.